Literature DB >> 2898784

Identification of carbohydrate structures that are possible receptors for Neisseria gonorrhoeae.

N Stromberg1, C Deal, G Nyberg, S Normark, M So, K A Karlsson.   

Abstract

Different strains and isogenic variants of Neisseria gonorrhoeae were assayed for their ability to bind glycolipids extracted from various sources. Among a large number of reference glycolipids, binding was observed only to lactosylceramide [Gal(beta 1-4)Glc(beta 1-1)Cer], isoglobotriaosylceramide [Gal(alpha 1-3)Gal(beta 1-4)Glc(beta 1-1)Cer], gangliotriaosylceramide [GalNAc(beta 1-4)Gal(beta 1-4)Glc(beta 1-1)Cer], and gangliotetraosylceramide [Gal(beta 1-3)GalNAc(beta 1-4)Gal(beta 1-4)Glc(beta 1-1)Cer]. The latter two glycolipids bound gonococci with the highest affinity. Lactosylceramide and gangliotriaosylceramide were found in glycolipid preparations from ME180 cells, an epithelial cell line derived from a human cervical carcinoma, and thus are possible receptors for gonococci. The gonococcal surface component that bound the above glycolipids is a protein distinct from pilin and protein II.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898784      PMCID: PMC280545          DOI: 10.1073/pnas.85.13.4902

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Some properties of a new epithelial cell line of human origin.

Authors:  J A Sykes; J Whitescarver; P Jernstrom; J F Nolan; P Byatt
Journal:  J Natl Cancer Inst       Date:  1970-07       Impact factor: 13.506

2.  Genetics of digalactoside-binding adhesin from a uropathogenic Escherichia coli strain.

Authors:  S Normark; D Lark; R Hull; M Norgren; M Båga; P O'Hanley; G Schoolnik; S Falkow
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

3.  Isoglobotriaosylceramide and the Forssman glycolipid of dog small intestine occupy separate tissue compartments and differ in ceramide composition.

Authors:  G C Hansson; K A Karlsson; G Larson; J M McKibbin; N Strömberg; J Thurin
Journal:  Biochim Biophys Acta       Date:  1983-01-07

4.  Gangliotetraosylceramide is a major glycolipid of epithelial cells of mouse small intestine.

Authors:  G C Hansson; K A Karlsson; H Leffler; N Strömberg
Journal:  FEBS Lett       Date:  1982-03-22       Impact factor: 4.124

5.  Attachment of gonococcal pili to lectin-resistant clones of Chinese hamster ovary cells.

Authors:  E R Gubish; K C Chen; T M Buchanan
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

6.  Lewis blood group fucolipids and their isomers from human and canine intestine.

Authors:  J M McKibbin; W A Spencer; E L Smith; J E Mansson; K A Karlsson; B E Samuelsson; Y T Li; S C Li
Journal:  J Biol Chem       Date:  1982-01-25       Impact factor: 5.157

7.  Glycosphingolipids of a green monkey kidney cell line (GMK AH-1). Evidence for a novel pentaglycosylceramide based on globotetraosylceramide.

Authors:  J Blomberg; M E Breimer; K A Karlsson
Journal:  Biochim Biophys Acta       Date:  1982-06-11

8.  Physical studies of cell surface and cell membrane structure. Deuterium nuclear magnetic resonance studies of N-palmitoylglucosylceramide (cerebroside) head group structure.

Authors:  R Skarjune; E Oldfield
Journal:  Biochemistry       Date:  1982-06-22       Impact factor: 3.162

9.  An antigen present in rat adenocarcinoma and normal colon non-epithelial stroma is a novel Forssman-like glycolipid based on isoglobotetraosylceramide.

Authors:  P Falk; J Holgersson; P A Jovall; K A Karlsson; N Strömberg; J Thurin; T Brodin; H O Sjögren
Journal:  Biochim Biophys Acta       Date:  1986-09-12

10.  Structural characterization of lactotetraosylceramide, a novel glycosphingolipid isolated from human meconium.

Authors:  K A Karlsson; G Larson
Journal:  J Biol Chem       Date:  1979-09-25       Impact factor: 5.157

View more
  28 in total

Review 1.  Genetic mechanisms and biological implications of phase variation in pathogenic neisseriae.

Authors:  T F Meyer; J P van Putten
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

Review 2.  Gonococcal vaccines.

Authors:  E C Tramont
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

3.  Interactions of Neisseria gonorrhoeae with human neutrophils: studies with purified PII (Opa) outer membrane proteins and synthetic Opa peptides.

Authors:  F L Naids; B Belisle; N Lee; R F Rest
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

4.  Antimicrobial interference with bacterial mechanisms of pathogenicity: effect of sub-MIC azithromycin on gonococcal piliation and attachment to human epithelial cells.

Authors:  G L Gorby; Z A McGee
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 5.  Common themes in microbial pathogenicity.

Authors:  B B Finlay; S Falkow
Journal:  Microbiol Rev       Date:  1989-06

6.  Cryptococcus neoformans, Candida albicans, and other fungi bind specifically to the glycosphingolipid lactosylceramide (Gal beta 1-4Glc beta 1-1Cer), a possible adhesion receptor for yeasts.

Authors:  V Jimenez-Lucho; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

Review 7.  Interactions of Neisseria gonorrhoeae with human neutrophils.

Authors:  R F Rest; W M Shafer
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

8.  Adherence to lipids and intestinal mucin by a recently recognized human pathogen, Campylobacter upsaliensis.

Authors:  F A Sylvester; D Philpott; B Gold; A Lastovica; J F Forstner
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

Review 9.  Aglycone modulation of glycolipid receptor function.

Authors:  C A Lingwood
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

10.  Up-regulation of human neutrophil receptors for Neisseria gonorrhoeae expressing PII outer membrane proteins.

Authors:  C F Farrell; R F Rest
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.